Sinew Pharma Inc.
TWO: 6634.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kai-Min Chu
- Employees
- 52
- Headquarters
- Taipei, Taiwan
- IPO year
- 2017
- Market cap
- NT$3.9B
- Website
- https://www.sinewpharma.com
Loading 6634…
Loading profile data…Frequently asked questions about 6634
What does Sinew Pharma Inc. (6634.TWO) do?
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clini...
Where does 6634.TWO trade?
Sinew Pharma Inc. (6634.TWO) trades on the Taipei Exchange.
What sector is 6634.TWO in?
Sinew Pharma Inc. (6634.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sinew Pharma Inc.?
Kai-Min Chu is the chief executive officer of Sinew Pharma Inc. (6634.TWO).
Where is Sinew Pharma Inc. headquartered?
Sinew Pharma Inc. is headquartered in Taiwan.
Does 6634.TWO pay a dividend?
Sinew Pharma Inc. (6634.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6634.TWO go public?
Sinew Pharma Inc. (6634.TWO) completed its initial public offering in 2017.